Semper Paratus Acquisition Corporation (NASDAQ:TVGN) Sees Significant Increase in Short Interest

Key Points

• Short Interest Surge: Semper Paratus Acquisition Corporation (NASDAQ:TVGN) experienced a dramatic increase in short interest, up by 3,719.3% to 1,860,000 shares as of July 15th, representing 4.6% of its total shares.
• Insider Sale: CEO Ryan H. Saadi sold over 1.4 million shares of stock on June 9th for approximately $1.77 million, reducing their ownership position by 1.22% while still holding 116.8 million shares.
• Institutional Investment Activity: Geode Capital Management and Barclays PLC were among institutional investors that increased their stakes in Semper Paratus Acquisition in the fourth quarter, highlighting ongoing institutional interest.

Semper Paratus Acquisition Corporation (NASDAQ:TVGN - Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,860,000 shares, anincreaseof3,719.3% from the June 30th total of 48,700 shares. Approximately4.6% of the shares of the company are sold short. Based on an average trading volume of 975,400 shares, the short-interest ratio is presently 1.9 days. Based on an average trading volume of 975,400 shares, the short-interest ratio is presently 1.9 days. Approximately4.6% of the shares of the company are sold short.

Insider Buying and Selling

In other Semper Paratus Acquisition news, CEO Ryan H. Saadi sold 1,438,206 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the completion of the sale, the chief executive officer directly owned 116,814,453 shares of the company's stock, valued at $143,681,777.19. This represents a 1.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 73.24% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Semper Paratus Acquisition

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in Semper Paratus Acquisition by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after purchasing an additional 107,566 shares during the period. Northern Trust Corp grew its holdings in shares of Semper Paratus Acquisition by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after acquiring an additional 13,595 shares during the period. Nuveen LLC acquired a new stake in Semper Paratus Acquisition during the 1st quarter valued at $97,000. XTX Topco Ltd acquired a new stake in Semper Paratus Acquisition during the 4th quarter valued at $55,000. Finally, Barclays PLC grew its holdings in Semper Paratus Acquisition by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after buying an additional 12,847 shares during the last quarter.

Semper Paratus Acquisition Stock Performance

NASDAQ TVGN traded up $0.01 on Friday, hitting $1.00. 373,209 shares of the company's stock were exchanged, compared to its average volume of 1,375,787. The firm's 50-day moving average price is $1.22 and its two-hundred day moving average price is $1.21. Semper Paratus Acquisition has a fifty-two week low of $0.26 and a fifty-two week high of $3.09.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a "buy" rating and set a $10.00 target price on shares of Semper Paratus Acquisition in a research report on Wednesday, June 18th.

About Semper Paratus Acquisition

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.